NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 percent to close at 24,893.49, for its fourth consecutive daily gain, while the S&P 500 Index spiked 1.34 percent to close at 2,698.63. The Nasdaq Composite Index surged 1.86 percent to close at 7,143.62.

"Anything with inflation seems like a hot button nowadays, but it is a bit of a red herring here: higher inflation and higher rates are symptoms of economic health. And while inflation is rising it's still below trend," said Karyn Cavanaugh, senior market strategist at Voya Financial, according to MarketWatch.

"At this point it's not inflation but reflation and the Fed will not pull the trigger that fast," said Cavanaugh.

RDI Initiates Coverage on:

Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR

Puma Biotechnology Inc.
https://rdinvesting.com/news/?ticker=PBYI

Nektar Therapeutics' stock jumped 11.02% Wednesday, to close the day at $84.00. The stock recorded a trading volume of 8,583,189 shares, which was above its three months average volume of 2,633,211 shares. In the last year, Nektar Therapeutics' shares have traded in a range of 12.50 - 99.02. The share price has gained 572.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $71.87 is greater than its 200-day moving average of $40.86. Shares of Nektar Therapeutics have gained roughly 16.67 percent in the past month and are up 40.66 percent year-to-date.

Access RDI's Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR

On Wednesday, shares of Puma Biotechnology recorded a trading volume of 2,032,209 shares, which was above the three months average volume of 897,587 shares. The stock ended the day 10.95% higher at 68.40. The share price has gained 141.27% from its 52 week low with a 52 week trading range of 28.35 - 136.90. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $81.20 is below its 200-day moving average of $98.82. Shares of Puma Biotechnology have fallen roughly 31.08 percent in the past month and are down 30.8 percent year-to-date.

Access RDI's Puma Biotechnology Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PBYI

Our Actionable Research on Nektar Therapeutics (NASDAQ:NKTR) and Puma Biotechnology Inc. (NASDAQ:PBYI) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com